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Abstract
Background: Detection, isolation, and identification of individual virus infected cells during long term infection are critical
to advance our understanding of mechanisms of pathogenesis for latent/persistent viruses. However, current approaches to
study these viruses in vivo have been hampered by low sensitivity and effects of cell-type on expression of viral encoded
reporter genes. We have designed a novel Cre recombinase (Cre)-based murine system to overcome these problems, and
thereby enable tracking and isolation of individual in vivo infected cells.
Methodology/Principal findings: Murine gammaherpesvirus 68 (MHV-68) was used as a prototypic persistent model virus.
A Cre expressing recombinant virus was constructed and characterised. The virus is attenuated both in lytic virus replication,
producing ten-fold lower lung virus titres than wild type virus, and in the establishment of latency. However, despite this
limitation, when the sEGFP7 mouse line containing a Cre-activated enhanced green fluorescent protein (EGFP) was infected
with the Cre expressing virus, sites of latent and persistent virus infection could be identified within B cells and
macrophages of the lymphoid system on the basis of EGFP expression. Importantly, the use of the sEGFP7 mouse line which
expresses high levels of EGFP allowed individual virus positive cells to be purified by FACSorting. Virus gene expression
could be detected in these cells. Low numbers of EGFP positive cells could also be detected in the bone marrow.
Conclusions/Significance: The use of this novel Cre-based virus/mouse system allowed identification of individual latently
infected cells in vivo and may be useful for the study and long-term monitoring of other latent/persistent virus infections.
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Introduction
The study of host-virus interactions in individual cell populations
in vivo is important for the development of disease control strategies.
This is particularly the case for viruses which establish life long
latent or persistent infections, frequently within low numbers of cells
with minimal virus gene expression, often in a number of different
cell types. The ability to ‘‘mark’’ infected cells in a readily detectable
manner would significantly enhance the study of these virus
infections. One approach, which has been investigated for several
latent herpesvirus infections including herpes simplex virus,
pseudorabies virus and Marek’s disease virus involves insertion of
a reporter gene such as b-galactosidase or green fluorescent protein
within the viral genome [1–5]. This technique requires the use of a
latency associated promoter to overcome the general repression of
viral promotersduringlatency, includingforeign promoters inserted
into the viral genome [6–9]. Even then, a latency associated
promoter may show tissue-specific expression. For example, the
HSV latency associated promoter has been shown to drive
expression of b-galactosidase long term in sensory neurons, but
the promoter is down-regulated in the CNS [10,11].
An alternative strategy that avoids many of the problems
associated with virally encoded reporter genes is to ‘mark’ the
infected cell using a reporter gene located within the host genome
that is activated upon virus infection. The Cre-recombinase (Cre)/
loxP site-specific recombination system has been used to mark cells
and tissues in vivo in nonviral systems investigating cellular
developmental patterns and differentiation [12–14]. In this system,
expression of a constitutively active reporter gene (eg b-
galactosidase or enhanced green fluorescent protein, EGFP) is
suppressed by the presence of an upstream stop codon flanked by
loxP sites (floxed). Cre expression results in excision of the floxed
stop codon allowing expression of the previously silenced reporter
gene. In vivo, the reporter gene can be activated by crossing the
reporter mouse with a mouse expressing constitutively active or
inducible Cre. Expression of Cre from a viral genome similarly
offers the potential to mark infected cells. As cells are permanently
marked by a single event and the reporter gene is located within
the host cell genome, this approach may also circumvent problems
associated with virus genome inactivation during latency.
In the present study, we have applied the Cre/loxP system to
investigate long-term in vivo infection with a prototypic latent/
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(MHV-68, also known as murid herpesvirus 4). MHV-68 is closely
related to the human gammaherpesviruses Epstein-Barr virus
(EBV) and Kaposi’s sarcoma associated herpesvirus (KSHV)
[15,16]. Studies in mice have shown MHV-68 latency to be
complex and involve a number of cell types including B cells,
macrophages, dendritic cells and lung epithelial cells. In long term
infections, the virus appears to reside in memory B cells whereas
the contribution of other cell populations to maintaining the
infection is not well understood [17–19]. The balance between
true latent infection, where there is limited gene expression, and
persistent infection involving on-going replication also has not
been elucidated.
In the present study, we constructed a recombinant MHV-68
expressing Cre and screened a variety of mouse lines expressing a
Cre-activatable reporter gene for expression of the reporter
following infection. One mouse line, sEGFP7, which has highly
accessible loxP sites expressing EGFP in over 90% of haemato-
poietic cells activated in ovo [20], proved particularly suited for
these studies. In sEGFP7 mice, MHV-68 infection (based on
EGFP positive cells) was detected in mediastinal lymph nodes
(MLNs) up to 80 days post-infection and in the bone marrow at
least until 165 days after infection. Because of the high level of
EGFP expression in this reporter system, activated cells could be
sorted by FACS and virus gene expression analysed. This marker
system provides a novel approach for investigating the nature and
distribution of virus-infected lymphoid/heamopoeitic cells and the
role of these cells in the establishment and maintenance of latent/
persistent virus infections.
Materials and Methods
Mice
ROSA26 GFP mice (B6;129-Gt(ROSA)26Sor
tm2Sho were pur-
chased from the Jackson Laboratory, USA. ROSA26 lacZ mice
were supplied by Dr Annemieke IJpenberg, MRC Human
Genetics Unit, Edinburgh. C57BL/6 and BALB/c mice were
purchased from Harlan UK Ltd (Oxon, UK). The sEGFP7 mouse
strain [20] was a gift from Dr Alexander Medvinsky, Institute of
Stem Cell Research, University of Edinburgh. All work was
carried out under a UK Home Office license according to the
Animals (Scientific Procedures) Act 1986.
Virus infections
Virus working stocks were prepared by infection of BHK-21
cells as previously described [21]. 4–8 week-old mice were
anaesthetized with Halothane (Rhone Merieux Ltd, Harlow,
Essex, U.K.) and inoculated intranasally with 4610
5pfu virus in
40l sterile PBS. At various times after infection mice were killed by
CO2 asphyxiation and tissues harvested for virus assays or
histology.
Construction of Recombinant Virus
Recombinant Cre expressing MHV-68 virus was constructed by
E/T recombination using a bacterial artificial chromosome (BAC)
containing the entire MHV-68 genome (kindly provided by Dr. U.
Koszinowski, Ludwig-Maximilians-Munchen, Munich)[22]. A
pcp015-based template plasmid (designated pcp015/Cre) contain-
ing the Cre gene under control of the RSV promoter and a 39
SV40 polyadenylation site was used as a template for generation of
the necessary PCR product for E/T recombination. The pcp015/
Cre also contains a FRT-flanked Kan
R marker for selection of
recombinants in bacteria (see below); and a synthetic intron within
the 59 coding region of Cre to restrict expression to eukaryotic
cells, as initially described by Smith and Enquist [23](Figure 1). E/
T recombination was performed essentially as described by Rue
[24]. The mutagenic PCR product was obtained from the
pcp015/Cre template by PCR amplification using mutagenic
primers MHVCre.for (59-GTGAGTGCTGACAGGCTTAAT-
AAAGAAAATGATTAAATGAAGTAAAACGACGGCCAGT-39)
and MHVCre.rev (59-GTTGTGTGTAGGAGGTGTGGAAA-
TAAAAACCCTTTAAAATTCAGGAAACAGCTATGAC -39).
These primers contain 41 nt homologous to the MHV-68
sequence flanking the site of insertion within the MHV-68 genome
and 17 nt homologous to the pcp015/Cre template. The Cre
cassette was inserted within the MHV-68 genome at nt 24700
between ORF11 and K3. E/T recombination was performed in
EL250s containing the MHV-68 BAC, and recombinants were
selected with chloramphenicol and kanamycin followed by Flp-
mediated removal of the FRT-flanked Kan
R marker. Recombi-
nant MHV-68 BACs were characterized by restriction digestion
combined with Southern analysis, as well as direct DNA
sequencing of the Cre expression cassette following PCR
amplification from the reconstituted viral genome.
Infectious virus was recovered from BAC DNA by Effectene
mediated transfection (Qiagen) into BHK cells. The BAC cassette
was removed from Cre-recombinant clones by self-excision. BAC
DNA was transfected into BHK cells in 6 well plates (Nunc). As
soon as colourless plaques (lacking the BAC cassette) were visible,
cultures were harvested and replated to limiting dilution in 96 well
plates. Wells containing single, colourless plaques were selected
and screened by PCR for intact Cre-recombinase.
Revertant BACs were made by allelic exchange using a shuttle
plasmid as previously described [22,25]. The wild type MHV-68
Hind I fragment (nt21965–26711) was cloned into the shuttle
plasmid pST76_SR and electroporated into DH10B cells
containing the Cre10–33 BAC. Transformed bacteria were then
propagated through a multi-step selection process and wild type
BAC was selected by PCR. Virus stocks were produced by
transfection of BAC DNA into BHK cells. BAC sequences were
excised from the reconstituted virus by passage through mouse
NIH 3T3 cells expressing Cre recombinase [26].
Southern Blot Analysis
Viral DNA was prepared from purified virions as previously
described [27]. 10 mg of viral DNA was digested with EcoRI,
fractionated on a 0.7% w/v agarose gel and transferred to nylon
membrane (Hybond
TM
-N+, GE Healthcare Ltd). The blot was
probed with [P
32]dCTP labeled probes for MHV-68 (nt 21199–
25494) and Cre-recombinase. Hybridisation was carried out in
Ultrahyb (Ambion) according to manufacturer’s directions and
radioactivity detected by exposure to ECL film.
Growth of virus in vitro
Single-step and multi-step growth in vitro was analysed by
infection of BHK-21 cells in suspension for 90 minutes at a
multiplicity of infection 5 (single-step growth) and 0.05 (multi-step
growth). Cells were washed with Glasgow’s medium four times to
remove unbound virus before seeding into 24-well plates. At
specific times post-infection cells were harvested and infectious
virus was determined by plaque assay. All infections were carried
out in duplicate, and each infection titrated in duplicate.
Analysis of Infected Tissues
Tissues were analysed for infectious virus by plaque assay and
latent infection by infective centre assay as previous described
[28]. For histological analysis, tissues were harvested into 4%
In Vivo Virus Tracking
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preserve EGFP fluorescence [29].
Immunohistochemistry
5–10 mm sections were cut onto poly-L lysine coated slides and
stored at 270
uC until required. Sections were blocked for 1 hour at
room temperature with 10% normal goat serum in Tris-buffered
saline and stained with primary antibodies in 2% NGS for 1 hour at
RT. Antibodies used were as follows: CD45R/B220 (RA3-6BS,
Pharmingen) to detect B cells, MOMA-1 (AbDSerotec) for
metallophilic macrophages, MOMA-2 (AbDSerotec) and F4/80
(CI:A3-1, AbDSerotec) for macrophages. Secondary antibody was
goat anti-rat alexafluor 594 (Molecular Probes). Nuclei were stained
with TOPRO3 (Molecular Probes). Sections were mounted in
Moliol and imaged with a Leica TCS-NT confocal microscope.
FACS analysis and sorting
Lymphocytes were teased from mediastinal lymph nodes,
resuspended in FACS buffer (PBS, 1%BSA, 0.1% sodium azide)
and stained with rat anti-mouse CD19 phycoerythrin (Caltag) and
hamster anti-mouse CD69 Tricolor (Caltag). Cells were gated on
EGFP positive lymphocytes and double stained populations were
sorted on a FACS Vantage with DiVa option (BD Bios-
ciences).
PCR
For analysis of transcription of ORF11 and K3 in vitro, C127
murine epithelial cells were infected at a multiplicity of infection of 5
and incubated for 18 hr at 37
uC. Monolayers were washed twice with
ice-cold PBS and RNA was extracted with RNAwiz (Ambion)
according to the manufacturer’s instructions. Contaminating DNA
was removed by treatment with DNAseI (DNA-Free, Ambion). For
analysis of sorted populations DNA and RNA were extracted from
sorted EGFP positive cells using the PicoPure DNA and the PicoPure
RNA extraction kits (Arcturus) respectively according to the
manufacturer’s instructions. cDNA was prepared from 5 mgR N A
or, for the sorted populations, total RNA recovered and PCR was
carried out as previously described [30] using the following primers:
Figure 1. Construction of recombinant MHV-68 expressing Cre-recombinase. A. Structure of the viral genome surrounding the insertion
site. Diagram shows the site of insertion, position of restriction sites and probes used for Southern analysis. B. EcoRI digests of BAC DNAs. o 11.4 kb in
wild type and revertant reduced to 10.4 in mutant clones. * shows bands containing 100 bp repeats. C. Southern blot of wild type (WT), Cre10–33 and
Cre-REV virus DNA digested with EcoRI and probed with an MHV-68 specific probe (nt 21199–25494) and a probe for Cre-recombinase.
doi:10.1371/journal.pone.0006492.g001
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GAGCTACTACACTACCTCCTG -39;O R F 1 1 f o r5 9-G G T -
GGA CTTTAAGCCCGATG -39; ORF11rev 59 –GGC AGC
T T CA C TG A CA C CA G3 9;O R F 7 3 F O R :5 9- TAGATCCAGGT-
GATCCTGTGGC -39; ORF73REV: 59- CCGCATAATC-
CATCTGATCCAT -39). PCR products were fractionated on an
agarose gel and visualized with ethidium bromide.
For quantitation of viral load in vivo DNA was prepared from
mediastinal lymph node cells harvested at day 5 post-infection
using the PureLink Genomic DNA Purification Kit (Invitrogen).
Real-time PCR for quantification of viral genome load was carried
out on 100 ng lymphocyte DNA using a Rotor-Gene (Corbett)
with the intercalating dye SYBR green. Regions of the M11,
ORF73 and M4 genes were amplified with specific primers
(ORF73QPCRfor 59-CGTCTGTCTCTCCTACATCTAAAC-
C-39; ORF73QPCRrev 59-CACCAACACTTCCCTCATCC-39;
M4-RTFor 59-CAC CTG AGA TCA AGT CTA TCG-39; M4-
RTRev 59-GTC GCA TAA CCA TGT CCA CG-39) and all
products analysed by a melt curve to confirm specificity. DNA
load was quantitated using cloned DNA and results were
normalized with a GAPDH real-time PCR.
Results
Construction of MHV-68 virus expressing Cre
To enable detection of virus infected cells in vivo, a virus expressing
a modified intron containing Cre-recombinase [23] was constructed
by mutagenesis of a MHV-68 bacterial artificial chromosome (BAC)
[22]. Linear recombination was used to insert a cassette containing
Cre under control of the RSV LTR into the MHV-68 genome
between the ORF11 and K3 genes at nt24700 (Figure 1A). Three
independent clones designated 6–3, 9–16 and 10–33 were selected.
Correct insertion of the Cre expression cassette within the MHV-68
BAC genome was confirmed by restriction digestion of BAC DNA
(Figure 1B) followed by Southern analysis, as well as by direct DNA
sequence analysis of a PCR product spanning the insertion site (data
not shown). Revertant BAC was constructed by allelic exchange and
confirmed as detailed above for Cre recombinant clones. Because
BAC recombination can result in loss of internal repeats, recombi-
nant BAC DNA preps were digested with EcoRI and monitored for
changes in repeat fragments. One clone, 6–3, showed a reduced
number of 100 bp repeats and therefore was not used for further
analysis. No other differences in repeats between the recombinant
clones and the parent were detected by this technique although allthe
BAC clones seem to have lost their 40 bp repeat (Figure 1B). Virus
was reconstituted by transfection of BAC DNA into MHV-68
permissive BHK cells. The presence of BAC sequences has been
shown to attenuate reconstituted MHV-68 virus [31]. Therefore
BAC sequences were removed from Cre expressing clones by self-
excision in BHK cells, indicating that the RSV LTR promoter is
active during lytic infection or by passage through a Cre-expressing
cell line (revertant). Once the BAC cassette was removed, the viral
genome was stable. Restriction digest followed by Southern blot
analysis of purified viral DNA was carried out to confirm the
genotype of the virus. Figure 1C shows that the expected digestion
pattern was observed. Virus stocks were monitored by PCR to
confirm the genotype routinely.
Characterisation of recombinant virus in vitro
In order to determine whether insertion of the Cre-recombinase
cassette affected growth of the recombinant virus, replication of
the Cre expressing viruses 9–16 and 10–33 was compared with
wild type (WT) BAC derived virus, PHA-4 and a revertant
constructed from the 10–33 BAC clone (REV) in vitro. Figure 2
shows single- and multi-step analysis of the viruses. The kinetics of
the one- step growth curve showed a delay in the growth of 10–33
and 9–16 when compared with the revertant or wild type MHV-
68. Both clone 9–16 and clone 10–33 also showed delayed growth
at early times in the multi-step analysis.
To determine whether insertion of the Cre expression cassette
affected transcription of the surrounding genes, C127 cells were
infected with WT or Cre10–33 and expression of K3 and ORF11
which flank the Cre insertion site was analysed by RT-PCR.
Figure 2C shows no difference in transcription of K3 and ORF11
in the Cre10–33 compared to WT-infected cells.
Characterisation of recombinant virus in vivo
Growth of viruses in vivo was assessed by intranasal infection of
BALB/c and C57Bl/6 mice. Similar results were observed with
both strains of mice and initial results showed that viruses derived
from 9–16 and 10–33 behaved identically. All further analysis was
therefore carried out with 10–33 derived virus (Cre10–33). Cre10–
33 replicated within the lung, although virus titres were consistently
lower than those obtained with wild type or revertant virus
(Figure 3A). The Cre10–33 virus was cleared with similar kinetics to
WT virus. Following replication in the lung, MHV-68 establishes
latent infection in the lymphoid system, initially within the
mediastinal lymph node where virus is associated with macrophag-
es, dendritic cells and B cells. The virus undergoes a B cell-
associated viraemia to infect other tissues such as the spleen where
the latent infection resides in the germinal centres. Latent infection
in lymphoid tissues is accompanied by lymphoproliferation.
Levels of latent virus in the mediastinal lymph nodes (MLN)
were determined by reactivation assay and quantitative PCR.
Assays for pre-formed infectious virus were carried out to confirm
that the reactivation assay was detecting latent virus and any
infectious virus was subtracted from the figures obtained in the
latency assay. In the majority of samples, infectious virus (Cre10–
33, WT or REV) was not detected in the MLNs. When infectious
virus was detected, the levels were always ,10% of the values of
latent virus. Five days pi, the number of latently infected cells in
the MLNs ranged from 12–634 cells per total lymph node for WT
and REV infected mice and 12–488 cells/MLN for the Cre 10–33
infected mice (Figure 3B). These data indicate that the initial phase
of latency established in Cre10–33 infected mice is similar to that
in mice infected with WT and REV.
However, by day 14, the Cre10–33 viral DNA load in the MLN
wasaround10fold lowerthaninWTorREVinfections(Figure3D)
and there few reactivatable cells present in the MLN (Figure 3C;
20–1340 infective centres per MLN for wild type and REV vs 0–50
for Cre10–33). These results are consistent with failure of Cre10–33
infected cells to amplify to the same extent as WT infected cells.
Analysis of latent infection in the spleen by reactivation assay
(Figure 3E) showed that Cre10–33 could not establish latent
infection at the same level as wild type at any time point and
resulted in lower levels of lymphoproliferation (Figure 3F).
These experiments indicate that insertion of the Cre-recombi-
nase cassette into MHV-68 has resulted in attenuation of the virus.
However, the virus is clearly capable of establishing latent
infection in the lymphoid system and therefore provides a useful
tool to determine whether virus encoded Cre-activation of a floxed
reporter in mice is able to identify latently infected cells in vivo.
Tracking virus infection of cells in the lymphoid system
In initial in vivo studies using Cre10–33, we were consistently
unable to detect EGFP or lacZ expressing cells by fluorescent
imaging or b-gal staining of infected ROSA26 EGFP or lacZ Cre
reporter mouse strains (data not shown). However, following
In Vivo Virus Tracking
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detected in MLN and spleen at various time points after infection.
This mouse strain expresses EGFP under control of the PGK
promoter. Expression has been studied in detail in the haemato-
poetic tissues and shown to be high level, readily detected by
FACS in all cell types and stable over long periods of time.
sEGFP7 mice were infected with Cre10–33 or WT virus, and at
days 4, 8, 12, 16, 28 and 80 pi MLNs were removed, frozen and
10 mm cryostat sections were prepared from each entire lymph
node. Figure 4A shows confocal images of EGFP positive cells in
Figure 2. In vitro characterisation of CreMHV-68 virus. To compare replication of Cre expressing MHV-68 clones 10–33 or 9–16 with wild type
PHA-4 and a revertant of 10–33 Cre-REV virus, BHK cells were infected with 5pfu/cell (single-step, A) or 0.05pfu/cell (multi-step B) and titred after
harvesting at specific time points post-infection. The data represent the mean +/2 the standard deviation. C. RT-PCR for detection of K3, ORF11 or
b2actin transcripts in C127 cells infected for 18 h with wild type (WT) or CreMHV-68 (Cre) or mock-infected.
doi:10.1371/journal.pone.0006492.g002
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examined by UV light microscopy and EGFP positive cells were
counted (Figure 4B). On day 4 pi, an average of 70 EGFP positive
cell was detected/lymph node. By day 8 post-infection, the
average number of positive cells/lymph node rose to over 6000,
and remained at this elevated level (4000–6000 cells) on days 12
and 16 pi. At later time points the average number of
EGFP positive cells/lymph node decreased and ranged from 50
to 150. Importantly, EGFP positive cells were still detectable 80
days pi. Thus, although the numbers of cells in the MLN
harbouring Cre10–33 virus, as determined by the reactivation
assay, appeared to be low at 2 weeks pi (,50 infective centres, see
Figure 3C), the large number of EGFP positive cells indicates that
a latent infection was readily detected at this time (Figure 4B),
reinforcing our conclusion that Cre10–33 can establish a latent
infection.
From initial replication in the MLN, MHV-68 is believed to be
disseminated to other tissues by infected B cells. Consistent with
Figure 3. In vivo characterisation of CreMHV-68 virus. BALB/c mice were infected intranasally with wild type MHV-68 (WT), Cre-recombinase
expressing MHV-68 (Cre10–33) or revertant virus (REV). Tissues were removed at various times and assayed for infectious virus by plaque assay, for
latent virus by a reactivation assay and for viral DNA by Q-PCR. A. Infectious virus in the lung; B. Latent virus in mediastinal lymph node (MLN) at day
5; C. Latent virus in the MLN day 14; D. Viral DNA load in MLN at day 14; E. Latent virus in the spleen; F. Spleen cell numbers. Solid line indicates mean.
doi:10.1371/journal.pone.0006492.g003
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12 (Figure 4A) and at subsequent times pi (data not shown). To
determine whether virus infected cells could be detected outside
secondary lymphoid organs, cytospins prepared from bone
marrow at days 16, 28, 80 and 165 were screened from EGFP
positive cells. Small numbers of EGFP positive cells (,1i n1 0
6)
were detected at day 28 (Figure S1) and were still detectable at day
165 pi (Figure 4C). Together these results show that the system
provides a powerful method of tracking virus infection in different
tissues in vivo.
Phenotyping of EGFP positive cells
The phenotype of EGFP positive cells in the MLNs of Cre10–
33 infected sEGFP7 mice was determined by confocal microscopy
of cryostat sections stained with antibody to B cells (B220) or a
mixture of anti-macrophage antibodies (MOMA1, MOMA2 and
F4/80) capable of detecting several macrophage subtypes. Figure 5
shows that EGFP positive B cells and macrophages were readily
detected at days 4 and 12pi providing direct visual evidence for
infection of these cell types and opening up the possibility of
selecting specific infected cells for further study.
Isolation of EGFP positive cells by flow cytometry
Thelarge numberofpositivecellspresentin theMLNsat days12–
16 pi suggested that isolation of virus positive cells by FACSorting
might be possible. The ability to select virus infected cells in this way
would make analysis of virus and host transcriptomes in specific cell
populations readily obtainable. Therefore, MLNs from sEGFP7 mice
infected with Cre10–33 or WT were analysed for EGFP expression.
Figure 6 shows that it was possible to detect EGFP positive cells in the
MLNs of Cre10–33 infected sEGFP7 mice by FACS analysis. In an
analysis of individual MLNs from 5 mice at day9 and 15 mice at
day16, the mean percentage of EGFP
+ cells was 0.25% of the gated
lymphocyte population and ,0.2% of the total population. Up to
19000 EGFP+ cells could be isolated from an individual MLN.
Representative data are shown in Table 1. Double staining of MLNs
for the B cell marker CD19 showed that the majority of the EGFP
positive cells were B cells (Figure 6A-C). EGFP cells were isolated by
Figure 4. Detection of EGFP positive cells in vivo. A. EGFP positive
cells in MLN and spleen of sEGFP7 mice infected with Cre10–33. Top
panels show EGFP only, bottom panels, EGFP plus TOPRO3 nuclear
staining. B. Total number of EGFP positive cells in MLNs over the course
of infection. Cell numbers determined by microscopy. Error bars
represent standard deviations from mean. C. EGFP positive cells in bone
marrow 165 days post-infection. Images obtained with a Leica confocal
microscope. Magnification640, negative; 663, positive.
doi:10.1371/journal.pone.0006492.g004
Figure 5. Phenotype of EGFP positive cells in the MLN of
sEGFP7 mice infected with Cre10–33. A-H day 4; I-P day 12. A-D
show images of MOMA1 positive macrophage, E-H and M-P show
detection of B220 positive B cells; I-L show macrophages stained with a
combination of anti-macrophage antibodies, MOMA1, MOMA2 and F4/
80. Sections imaged with a Leica confocal microscope. Magnifica-
tion663.
doi:10.1371/journal.pone.0006492.g005
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and RT-PCR for the presence of virus genome and transcripts.
Figure 6D shows that viral DNA was detectable in the EGFP positive
population and the latency associated transcript ORF73 was readily
detected.
Activated B cells were selected by FACSorting of EGFP
+,
CD19
+, CD69
+ cells from MLNs at day16 pi. Analysis of these
cells by quantitative RT-PCR demonstrated the presence of the
latency associated transcript ORF73 (Figure 6E) but expression of
the lytic cycle gene M4, which is more readily detectable than
ORF73 in lytically infected cells [32] could not be detected thus
providing evidence for latent infection in this cell population. The
system thus provides a powerful means of isolating individual
infected cell populations and potentially enabling fundamental
questions to be addressed.
Discussion
We have developed a novel system to detect and characterise
virus-infected cells in vivo. The system exploits a Cre-expressing
virus and mice containing EGFP under the control of a floxed
transcription stop codon. MHV-68 was used to model infection of
the lymphoid system enabling fundamental questions to be
addressed on the kinetics of latent infection, the detection of
novel sites of latency and the potential to explore host and virus
gene expression in individual infected cells at different stages
following infection. A key feature of this model was the availability
of the sEGFP7 mouse strain as other mouse strains investigated did
not allow detection of infected cells.
The Cre-loxP system has been used to identify neurons latently
infected with HSV. This involved a Cre expressing HSV and the
ROSA26R mice carrying a lacZ reporter [33]. In our model we
were unable we were unable to detect lacZ expression in the
lymphoid system of ROSA26R mice, possibly reflecting lower
promoteractivityinthistissue.Further,theuseofanEGFP reporter
has the advantage that live cells can be detected and sorted without
the need to carry out ex vivo staining. A related approach relying on
tissue specific expression of Cre-recombinase and an EGFP gene
preceded by a ‘‘floxed’’ stop codon inserted into the MCMV
genome has been used to track lytic infection in vivo. In this system,
lytically infected cells express EGFP and progeny virus permanently
encode activated EGFP gene. Thus the contribution of different cell
types to lytic virus replication and spread of infectious virus can be
tracked. This system, however, unlike the system described here
does not mark latently infected cells [34].
The presence of the Cre cassette clearly attenuates the virus
both in vivo and in vitro. In vivo the virus replicates less efficiently in
the lung and, whereas the early stages (day 5) in the establishment
of a latent infection are similar to wild type virus, by day 14 the
number of latently infected cells as determined by the infective
centre assay is greatly reduced and the viral DNA loads are
around 10 fold less than wild type. These data together with
the numbers of EGFP
+ cells in the MLN at day 16 measured
by both FACS and microscopic analysis are consistent with a
failure of the virus to amplify to the same levels as wild type
virus.
The reason for the attenuation is not clear. The RSV LTR is
active during lytic infection, as shown by the ability of the BAC to
self-excise, and the ability to detect EGFP expression in the MLN
where the predominant infection is latent strongly suggests it is
active during at least the early stages of latent infection. It is
possible that RSV promoter activity within the virus genome alters
the activity of viral promoters. Consistent with this idea, the
insertion of the lacZ under the human cytomegalovirus immediate
early promoter has been shown to alter the replication of MHV-68
in vivo [35]. Downstream effects from the RSV promoter could
affect virus replication both in vitro and in vivo. Attenuation of virus
replication in the lung and latent virus load in the spleen may be
related to EGFP expression although the sEGFP7 line is on a
C57Bl/6 background and EGFP has been reported to have a
minimal immunogenic effect in this mouse strain [36]. In
preliminary experiments we have found that depletion of CD8
T cells in Cre10–33 infected sEGFP7 mice results in 1006higher
levels of reactivatible virus in the spleen at days 12 and 20. It is
possible, therefore, that the RSV promoter is driving expression of
a virus gene which is a CD8 target.
Although the virus is attenuated, it can to establish a latent
infection. Within the MLN, the number of infected cells increased
over the first week reaching a plateau around day 8 and remained
elevated for a further 8 days. By 4 weeks post-infection, the
number of infected cells had decreased. The kinetics of latent
infection are similar to those demonstrated by infective centre
assays as a measure of reactivation from latency and by Q-PCR as
a true measure of cells harbouring viral DNA. The method
defines an ‘acute phase’ of latency in which there is a rapid
expansion of latently infected cells that act as a reservoir for
seeding by the vascular system to other tissues. In this model,
EGFP positive cells are detected in the spleen by day 12 post-
infection and in the bone marrow there are infected cells present
from day 28 to at least 165 days post-infection. The bone marrow
has been identified as a site of latent infection [37] but the nature
of the infected bone marrow cell has not been determined. This
technique offers the potential for identifying the infected bone
marrow cells and for detecting and identifying other novel
infected cell types.
EGFP
+ cells in the MLN can be selected by FACS presenting a
powerful approach to investigate in detail transcription patterns in
cells of different phenotypes at different time points during the course
of infection. We have sorted EGFP
+ CD19
+ CD69
+ cells and
quantified ORF73 and M4 expression in this population providing
evidence that the cells are latently infected. Analysis of virus gene
expression in B cell subsets isolated by FACSorting has shown that,
14 days pi, virus gene expression is restricted and depends on the
differentiation stage of the B lymphocyte [17]. The technology we
describe offers the potential to enhance and extend these studies using
Table 1. Percentages of EGFP
+ cells in mediastinal lymph
nodes and numbers of cells recovered from total lymph node
by FACSort.
Mouse
number
Day post-
infection
% lymphocytes
EGFP
+
Number of cells
sorted/MLN
1 9 0.1 10000
2 9 0.1 4231
3 9 0.1 3959
4 16 0.1 2800
5 16 0.1 3704
6 16 0.1 2399
7 16 1.6 18938
8 16 0.1 5742
9 16 0.1 10397
19 16 0.1 2107
doi:10.1371/journal.pone.0006492.t001
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proportion of virus infected cells within the sorted cell populations is
very low. This will be particularly important in analysing small
numbers of latently infected cells situated in different tissue
compartments, where a variable state of latency may exist.
In summary, the application of Cre-loxP technology provides
new opportunities to study the molecular basis of persistence/
latency in cells of the immune system identified at different times
after infection. Furthermore, one important application of this
approach is the discovery of new cell types associated with
persistent/latent virus infection.
Supporting Information
Figure S1 EGFP postive cells in bone marrow 28 days post
infection. Images obtained with a Leica confocal microscope.
Magnification663.
Found at: doi:10.1371/journal.pone.0006492.s001 (1.95 MB TIF)
Figure 6. FACS analysis of lymphocyte population of MLNs from sEGFP7 mice 16 days after infection. A. sEGFP7 mouse infected with
wild type virus (negative control); sEGFP7 mice infected with Cre (10–33) unstained (B) or stained (C) with CD19-PE; D. DNA from sorted EGFP positive
cells was subjected to PCR using primers for MHV-68 ORF73 together with positive (MHV-68 DNA) and negative (H2O) controls. E. Quantitative RT-PCR
for viral transcripts in EGFP
+ CD19
+, CD69
+ cells. When quantitative PCR was carried out on equivalent amounts of DNase treated RNA, GAPDH was
undetectable and copy numbers of ORF73 were ,0.05 of those of cDNA.
doi:10.1371/journal.pone.0006492.g006
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